CAR-T 19 Combined with Reduced-dose PD-1 Blockade Therapy for Treatment of Refractory Follicular Lymphoma: A Case Report

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Oct 16

PMID 31611950

Citations 23

Authors

Jia Wang

Qi Deng

Yan-Yu Jiang

Rui Zhang

Hai-Bo Zhu

Juan-Xia Meng

Yu-Ming Li

Affiliations

Soon will be listed here.

Abstract

Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has changed the typical outcomes of relapsed/refractory B-cell leukemia and lymphoma. However, treatment effectiveness for patients with relapsed/refractory B-cell non-Hodgkin lymphoma has been less satisfactory compared with patients with B-cell acute lymphoblastic leukemia. The present study described a case of refractory follicular lymphoma. A high expression of programmed cell death 1 (PD-1) was measured on CD3 T cells (80.90%) in peripheral blood samples obtained from the patient enrolled in this study, indicating that treatment with autologous CAR-T 19 cell therapy may not be successful. Therefore, a therapy regimen consisting of CAR-T 19 cells in combination with a reduced dose of nivolumab (1.5 mg/kg) for PD-1 blockade was used. A low dose of PD-1 blockade therapy was used to reduce the adverse effects associated with the combination of a PD-1 inhibitor and CAR-T 19 cells. This salvage therapy resulted in remission that lasted for >10 months.

Citing Articles

CAR-NK cells in combination therapy against cancer: A potential paradigm.

Li J, Hu H, Lian K, Zhang D, Hu P, He Z Heliyon. 2024; 10(5):e27196.

PMID: 38486782 PMC: 10937699. DOI: 10.1016/j.heliyon.2024.e27196.

Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients.

Zhou Y, Mu W, Wang C, Zhuo Z, Xin Y, Li H BMC Cancer. 2023; 23(1):1019.

PMID: 37872514 PMC: 10591343. DOI: 10.1186/s12885-023-11536-4.

Involving stemness factors to improve CAR T-cell-based cancer immunotherapy.

Noraldeen S, Rasulova I, Lalitha R, Hussin F, Alsaab H, Hussien Alawadi A Med Oncol. 2023; 40(11):313.

PMID: 37779152 DOI: 10.1007/s12032-023-02191-7.

[CAR-T cell combined with PD-1 inhibitor in the treatment of high-risk chronic lymphocytic leukemia with Richter's transformation: two cases report and literature review].

Zhou J, Zong X, Zhang Y, Geng H, Li C Zhonghua Xue Ye Xue Za Zhi. 2023; 44(5):427-430.

PMID: 37550195 PMC: 10440618. DOI: 10.3760/cma.j.issn.0253-2727.2023.05.013.

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy.

Harrer D, Dorrie J, Schaft N Int J Mol Sci. 2023; 24(3).

PMID: 36768665 PMC: 9916546. DOI: 10.3390/ijms24032342.

References

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

Laubli H, Balmelli C, Bossard M, Pfister O, Glatz K, Zippelius A . Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer. 2015; 3:11. PMC: 4404586. DOI: 10.1186/s40425-015-0057-1. View

Annibali O, Crescenzi A, Tomarchio V, Pagano A, Bianchi A, Grifoni A . PD-1 /PD-L1 checkpoint in hematological malignancies. Leuk Res. 2018; 67:45-55. DOI: 10.1016/j.leukres.2018.01.014. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Jurinovic V, Kridel R, Staiger A, Szczepanowski M, Horn H, Dreyling M . Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood. 2016; 128(8):1112-20. PMC: 5457130. DOI: 10.1182/blood-2016-05-717355. View

Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M . Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2016; 52(2):216-221. DOI: 10.1038/bmt.2016.213. View

Wang C, Thudium K, Han M, Wang X, Huang H, Feingersh D . In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014; 2(9):846-56. DOI: 10.1158/2326-6066.CIR-14-0040. View

Jaspers J, Brentjens R . Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther. 2017; 178:83-91. PMC: 5601024. DOI: 10.1016/j.pharmthera.2017.03.012. View

10.

Kochenderfer J, Dudley M, Kassim S, Somerville R, Carpenter R, Stetler-Stevenson M . Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2014; 33(6):540-9. PMC: 4322257. DOI: 10.1200/JCO.2014.56.2025. View

11.

Naidoo J, Page D, Li B, Connell L, Schindler K, Lacouture M . Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015; 26(12):2375-91. PMC: 6267867. DOI: 10.1093/annonc/mdv383. View

12.

Schuster S, Svoboda J, Chong E, Nasta S, Mato A, Anak O . Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017; 377(26):2545-2554. PMC: 5788566. DOI: 10.1056/NEJMoa1708566. View

13.

Batlevi C, Matsuki E, Brentjens R, Younes A . Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2015; 13(1):25-40. PMC: 4916838. DOI: 10.1038/nrclinonc.2015.187. View

14.

Li S, Siriwon N, Zhang X, Yang S, Jin T, He F . Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. Clin Cancer Res. 2017; 23(22):6982-6992. DOI: 10.1158/1078-0432.CCR-17-0867. View

15.

Huang A, Postow M, Orlowski R, Mick R, Bengsch B, Manne S . T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017; 545(7652):60-65. PMC: 5554367. DOI: 10.1038/nature22079. View

16.

Zou W, Wolchok J, Chen L . PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016; 8(328):328rv4. PMC: 4859220. DOI: 10.1126/scitranslmed.aad7118. View

17.

Brudno J, Kochenderfer J . Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127(26):3321-30. PMC: 4929924. DOI: 10.1182/blood-2016-04-703751. View

18.

Martelli M, Ferreri A, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri S . Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013; 87(2):146-71. DOI: 10.1016/j.critrevonc.2012.12.009. View